- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05383144
Deformable Image Registration for Breast Adaptive Tomotherapy (DIRB-ATOM)
April 6, 2023 updated by: Institut de cancérologie Strasbourg Europe
Quantitative Evaluation of the Performance of a Deformable Registration Algorithm: Single-center Study Aimed at Implementing a New Off-line Adaptive Radiotherapy Technique in the Treatment of Breast Cancer by Tomotherapy
The radiotherapy treatment plan (also called dosimetry) used for all treatment sessions is based on the dosimetric scanner.
During the sessions, the anatomy of the breast may vary, and these variations may impact the quality of the treatment.
Adaptive radiotherapy is a new technique that allows these changes to be taken into account during treatment by automatically rescheduling the treatment for each session.
The proposed trial aims to clinically evaluate one of these adaptive radiotherapy tools (PreciseART) based on deformable registration in order to determine if it can be used in daily practice in the treatment of breast cancer by tomotherapy.
The trial will also clarify whether factors, such as duration of treatment, impact the quality of this algorithm.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The dosimetric scanner needed to calculate the dose to be delivered to the tissues will be carried out according to the standard practice.
The treatment plan will be carried out by the physicist in accordance with the dose constraints and validated by the radiation therapist.
Each treatment session is preceded by positioning imaging to ensure high precision in the treated area.
During the first session, the acquisition of the positioning scanner will take into account the entire region of the target volume in accordance with the classic treatment protocol.
Usually, the positioning scans of the remaining sessions are carried out on a smaller area around the operating bed in order to reduce the acquisition time.
However, in the context of this study, mid- and end-of-treatment positioning scans will be acquired over the same exploration range as on the first day.
These scanners will make it possible to compare the contouring work carried out manually by the radiotherapist and that obtained by the deformable registration algorithm.
Study Type
Observational
Enrollment (Actual)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Strasbourg, France, 67033
- Institut de cancérologie Strasbourg Europe
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
Female
Sampling Method
Probability Sample
Study Population
Adult followed in the context of unilateral breast cancer, treated with chemotherapy and/or neoadjuvant hormone therapy, with partial or total mastectomy and then with adjuvant radiotherapy.
Description
Inclusion Criteria:
Female
- With invasive breast carcinoma (or axillary lymphadenopathy whose pathological examination is compatible with the origin of breast cancer but without an identified primary breast tumor)
- Breast surgery (conservative surgery or mastectomy)
- Treated by (neo)adjuvant chemotherapy or hormonotherapy
- eligible to normo-fractionated breast radiotherapy in 25 sessions of 2 Gray or 15 sessions of 2.67 Gray, associated or not to bed irradiation whatever the delivered dose
- eligible to an irradiation of sus-clavicular, inner mammary chain or axillary lymph nodes
- With helicoidal tomotherapy
Exclusion Criteria:
- Absence of indication for breast radiotherapy
- Absence of indication for lymph nodes irradiation
- partial irradiation of breast
- in situ carcinoma
- intranodal isolated tumor cells
- radiotherapy on prosthesis or surgically reconstructed breast
- antecedent of breast irradiation opr homolateral lymh node irradiation
- bilateral breast cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences between dosimetric metrics on deformed and delineated contours.
Time Frame: Before treatment
|
Description of the differences between metrics calculated on delineated contours and contours deformed by artificial intelligence
|
Before treatment
|
|
Differences between dosimetric metrics on deformed and delineated contours.
Time Frame: Mid-treatment : after fraction 7 for patients with 15 fractions (theoretically at day 9) or after fraction 12 for patients with 25 fractions (theoretically at day 16)
|
Description of the differences between metrics calculated on delineated contours and contours deformed by artificial intelligence
|
Mid-treatment : after fraction 7 for patients with 15 fractions (theoretically at day 9) or after fraction 12 for patients with 25 fractions (theoretically at day 16)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 27, 2022
Primary Completion (Actual)
April 4, 2023
Study Completion (Actual)
April 4, 2023
Study Registration Dates
First Submitted
April 28, 2022
First Submitted That Met QC Criteria
May 16, 2022
First Posted (Actual)
May 19, 2022
Study Record Updates
Last Update Posted (Actual)
April 7, 2023
Last Update Submitted That Met QC Criteria
April 6, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
Clinical Trials on Complete Positioning scans
-
Poudre Valley Health SystemRecruiting
-
Cairo UniversityCompletedPneumonia, Ventilator-Associated
-
FLUIDDA nvTerminatedBronchiolitis Obliterans | Lung Transplant RejectionBelgium
-
Yuhu MaNot yet recruitingPostoperative Hypoxemia | Position Differences
-
University of MichiganCompleted
-
Ayub Medical College, AbbottabadAyub Teaching HospitalCompletedCOVID-19 Pneumonia | COVID-19 Acute Respiratory Distress Syndrome | Prone PositioningPakistan
-
University of Health Sciences Balikesir Hospital...Not yet recruitingGeriatric | Hypotension Drug-Induced | Spinal Aneshtesia | Orthopedic Surgery Patients
-
University of TennesseeRecruitingLabor Onset and Length Abnormalities | Labor Long | Prolonged Labor | Labor; PoorUnited States
-
University Magna GraeciaCompletedUrinary IncontinenceItaly
-
Manchester University NHS Foundation TrustUniversity College, London; University Hospital Southampton NHS Foundation... and other collaboratorsRecruitingObstructive Sleep Apnea | Cleft PalateUnited Kingdom